OptiBiotix receives CE mark approval for SlimBiome® weight management product
OptiBiotix Health has announced that its award-winning weight management product, SlimBiome®, has been granted CE mark approval as a medical device. SlimBiome® actively helps people to consistently manage their weight loss by reducing their food intake while at the same time reducing food cravings.
SlimBiome® contains non-digestible prebiotic fibres, which increase microbial diversity. An increase in the diversity of microbes (microbiome) in the gut has been shown to help people lose weight more quickly and most importantly sustain this weight loss. In addition to prebiotic fibres, SlimBiome® also contains a water-soluble dietary fibre that promotes a feeling of fullness and reduces post-meal surges in insulin and glucose, and a mineral which helps to maintain a healthy metabolic rate.
- Feel fuller and are less hungry.
- Experience fewer food cravings.
- Change their food choice to eat less sweet and fatty foods.
Stephen O'Hara, CEO of
Following the CE mark approval, OptiBiotix announced that SlimBiome® will now be made available as a medical product, SlimBiome® Medical. SlimBiome® Medical will be manufactured in Europe and sold in boxes of 30 single dose sachets as SlimBiome® Medical to pharmacies and major retailers as a clinically proven solution to promote weight loss. The product can be used by itself, or as part of a calorie restriction diet to reduce hunger and food cravings to improve compliance, and help people to achieve sustainable weight loss.
SlimBiome® is currently available as a functional food ingredient, and is the active ingredient in the GoFigure range of diet products.
SlimBiome® has already won several major industry awards, including Weight Management Ingredient of the Year at Vitafoods 2018, and the award for 'Best Functional Ingredient for Health and Well Being' at Food Matters Live in 2017.
OptiBiotix was formed in March 2012 by Stephen O’Hara to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
 Studies are ‘in press’ awaiting publication.
 Participants either took SlimBiome® on its own, or as an ingredient in the GoFigure diet products.
FOR MEDIA INFORMATION:
On behalf of Optibiotix Health plc
Simon Vane Percy
Vane Percy & Roberts
(T) +44 (0) 1737 821890